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OBJECTIVES: 1) To characterize the impact of multiple myeloma on the quality of life of patients treated in two
public institutions in Sa˜o Paulo State, Brazil, using a generic Short Form 36 Health Survey and a questionnaire
specific for oncologic patients (QLQ-C30) upon diagnosis, after the clinical treatment, and at day +100 after
autologous stem cell transplantation; 2) to evaluate whether autologous stem cell transplantation can improve the
quality of life of our economically challenged population aside from providing a clinical benefit and disease control.
METHODS:We evaluated 49 patients with multiple myeloma (a total of 70 interviews) using the two questionnaires.
The scores upon diagnosis, post-treatment/pre-autologous stem cell transplantation, and at D+100 were compared
using ANOVA (a comparison of the three groups), post hoc tests (two-by-two comparisons of the three groups), and
paired t-tests (the same case at two different times).
RESULTS : Of the included patients, 87.8% had a family budget under US $600 (economic class C, D, or E) per month.
The generic Short Form 36 Health Survey questionnaire demonstrated that physical function, role-physical, and
bodily pain indices were statistically different across all three groups, favoring the D+100 autologous stem cell
transplantation group (ANOVA). The questionnaire specific for oncologic patients, the QLQ-C30 questionnaire,
confirmed what had been demonstrated by the Short Form 36 Health Survey with respect to physical function and
bodily pain, with improvements in role functioning, fatigue, and lack of appetite and constipation, favoring the
D+100 autologous stem cell transplant group (ANOVA). The post hoc tests and paired t-tests confirmed a better
outcome after autologous stem cell transplantation.
CONCLUSION: The questionnaire specific for cancer patients seems to be more informative than the generic Short
Form 36 Health Survey questionnaire and reflects the real benefit of autologous stem cell transplantation in the
quality of life of multiple myeloma patients in two public Brazilian institutions that provide assistance for
economically challenged patients.
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INTRODUCTION
Multiple myeloma (MM) has a significant impact on a
patient’s quality of life (QoL) because the patient becomes
dependent on others, even for routine activity execution and
personal care.1 MM treatment includes therapy for the
underlying disease and supportive therapy to enhance
QoL. The aim of MM treatment is to control the disease,
particularly its bone destruction. Healthcare professionals
involved in MM treatment must minimize any post-
treatment complications and ensure the best possible long-
term QoL for each patient. International studies assessing the
QoL of patients with MM were validated in developed
countries. In Brazilian public hospitals, MM patients have
important related social, economic, and emotional difficul-
ties, including the following: a low family budget, unem-
ployment, difficulties in receiving government financial
support after diagnosis, a long distance between the home
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and the hospital, transportation difficulties for disable
patient, the absence of a caregiver, and poor family support
related to social problems. Because of these difficulties, we
believe that it is important to evaluate whether high-dose
chemotherapy followed by autologous hematopoietic stem
cell transplantation (ASCT), could improve the QoL of our
patients (other than clinical benefits and disease control).
Therefore, the aim of this study was to characterize the
impact of MM in the QoL of patients treated in two public
institutions in Sa˜o Paulo State, Brazil, using a generic Short
Form 36 Health Survey and a questionnaire specific for
oncologic patients (QLQ-C30) upon diagnosis, after the
clinical treatment, and at day +100 after ASCT. We also
evaluated whether ASCT improves the QoL of our
economically challenged population.
METHODS
Study design. Between March 2006 to August 2007, we
evaluated 49 MM patients who were treated at Disciplina de
Hematologia e Hemoterapia, Universidade Federal de Sa˜o
Paulo Sa˜o Paulo/UNIFESP (a total of 26 patients) and Santa
Casa de Miserico´rdia de Sa˜o Paulo (a total of 23 patients). We
did not include patients with solitary plasmacytoma or
monoclonal gammopathy of undetermined significance or
patients without a physical/emotional condition for a 30-
minute interview. Patients who were more than 70 years old,
had chronic renal insufficiency requiring dialysis, congestive
cardiac insufficiency, or cardiac amyloidosis did not undergo
high-dose chemotherapy followed by ASCT. Written informed
consent was obtained from all of the patients, and the study
was approved by the ethics committees of these two institu-
tions (CEP no. 0249/06 and CEP no. 374/06, respectively).
Economic class assessment. A questionnaire that defined the
economic classes of each of the 49 MM patients was applied
using Brazil’s Economic Classification (www.ibope.com.br).
This classification was created in 2000 and considers how
many bathrooms, color TVs, radios, cars, vacuum cleaners,
washing machines, DVD players, refrigerators, freezers and
housemaids are in the patient’s household. It also considers
the highest education level of any household member (not
necessarily the MM patient). The final score classifies the
patient within one of seven economic classes (A1/2, B1/2,
C, D, or E). Based on the dollar value in 2000, an A1-class
patient has a family budget of US $5,000/month, and an E-
class patient has a family budget of US $130/month.
Quality-of-life questionnaires. Two quality-of-life instruments
were used in this study: the Short Form 36 Health Survey (SF-
36)2 and the European Organization for Research and
Treatment of Cancer (EORTC) Quality of Life Questionnaire-
C30 (QLQ-C30).3 The SF-36 is an internationally validated
instrument that can be self-administered or administered over
the phone by trained health professionals. It includes a multi-
item scale that assesses the following eight health domains:
physical function, role-physical, bodily pain, general health, vitality,
social function, role-emotional, and mental health. The physical and
mental components are summaries of the eight domains in the
SF-36 questionnaire. These domains have final scores between
0 and 100, where zero corresponds to the worst health state,
and 100 corresponds to the best health state.2 This question-
naire has been adapted and validated in Portuguese since
1999.2 The EORTC QLQ-C30 questionnaire is an internationally
validated instrument in Portuguese (Brazilian) and incorpo-
rates nine multi-item scales: five functional scales (physical, role,
cognitive, emotional and social); three symptom scales (fatigue,
pain, and nausea and vomiting); and global health and quality-of-
life scales (dyspnea, insomnia, lack of appetite, constipation, diarrhea,
and financial difficulty).3 These scales have final scores between 0
and 100, where high scores indicate better outcomes for the
functional scales and global health and worse outcomes for the
symptom and quality-of-life scales. Authorizations for the use
of the SF-36 and QLQ-C30 questionnaires (Portuguese
[Brazilian] version) were given by Dr. Marcos Bosi Ferraz
and Dr. Rozana M. Ciconelli and the EORTC Quality of Life
Group, respectively, in May 2006. These questionnaires were
administered to patients upon diagnosis, after the clinical
treatment (post-treatment/pre-ASCT), and at day +100 after
ASCT (D+100 ASCT). Of the 49 patients, 29 were evaluated
upon diagnosis, 27 were evaluated post-treatment/pre-ASCT
(9 patients were also evaluated at diagnosis), and 14 were
evaluated at D+100 ASCT (12 patients were also evaluated
post-treatment/pre-ASCT). Thus, the 49 MM patients gener-
ated 70 total completed interviews, as depicted in the flow
diagram of the study design (Figure 1). All of the interviews
were conducted by one of the principal researchers (V.C.S.),
and the average time required to complete the questionnaires
was approximately 30 minutes (while the patient was waiting
for the physician consultation).
Statistical analysis. The sample classification (according to
sex, isotype, disease stage, and the International Staging
System [ISS]) was expressed as absolute numbers and
as relative percentages. Chi-squared tests were used to
compare the categorical variables among the groups. The
ages were expressed as means ¡ standard deviations. For
the SF-36 and QLQ-30 questionnaire score analyses, we
followed all of the directions provided by each responsible
group.2,4,5 The interviews that were generated by the
quality-of-life questionnaires upon diagnosis, post-treat-
ment/pre-ASCT and at D+100 ASCT were compared using
ANOVA (for comparisons of the three groups), post hoc tests
(for two-by-two comparisons of the three groups) and
paired t-tests (the same case at two different times). The
level of significance for all of the statistical tests was 5%.
RESULTS
There were no statistically significant differences among
the three evaluated groups with respect to sex, age, isotype,
clinical stage, and ISS (Table 1). With respect to economic
class, the following classification was obtained: 4.0% in B1,
8.2% in B2, 63.3% in C, 22.5% in D, and 2.0% in E. According
to our classification, 87.8% of the included patients had a
familial budget of less than US $600 per month (i.e.,
economic classes C, D, or E). The generic SF-36 question-
naire demonstrated that physical function, role-physical, and
bodily pain were statistically different across all three groups
and favored the D+100 ASCT group (ANOVA; Table 2). The
physical component portion of the SF-36 had borderline
statistical significance and favored the D+100 ASCT, which
corresponds to the physical function, role-physical, and bodily
pain domains. The QLQ-C30 questionnaire confirmed the
SF-36 results with respect to physical function and bodily pain
and improved role functioning, fatigue, the lack of appetite and
constipation and usually favored the D+100 ASCT group
(ANOVA; Table 3). The significant results obtained using
the post hoc tests (two-by-two comparisons of the three
groups,) are shown in Table 4. The outcomes were better
after treatment (including ASCT). Paired t-tests (comparing
Quality of life in Brazilian MM patients
Etto LY et al.
CLINICS 2011;66(11):1855-1859
1856
the same case at two different times) demonstrated
improvements in fatigue (p= 0.036) and global health
(p= 0.045) after clinical treatment compared to the time of
diagnosis (as determined by the QLQ-C30). This finding
confirms the post hoc results. Paired t-tests demonstrated
improvements in physical function (p= 0.022) and role-
emotional (p= 0.043) when the patients at the end of their
clinical treatments were compared to the patients at D+100
ASCT using the SF-36 questionnaire. The QLQ-C30 detected
significant improvements in the global health (p= 0.034) and
social characteristics (p= 0.044) when the same patients in
the two aforementioned situations were compared.
DISCUSSION
In this study, we characterized the impact of MM on the
QoL of patients treated in two public institutions in Sa˜o
Paulo State, Brazil, using a generic (SF-36) questionnaire and
a questionnaire specific for oncologic patients (QLQ-C30)
upon diagnosis, after clinical treatment and at day +100 after
ASCT. The SF-36 is an internationally validated instrument
that can be self-administered or given over the phone. This
questionnaire has been adapted and validated in
Portuguese since 1999.2 We found only one previous report
that described the use of the SF-36 questionnaire in MM
patients to compare QoL pre- and post-kyphoplasty.6
Recently, the EORTC validated a disease-specific question-
naire module (QLQ-MY20) for patients with MM. The study
was performed through the EORTC Quality of Life Group
using clinical trials in seven countries. The social support
scale was removed in the final analysis because it did not
discriminate between the groups in this population.7 The
differences observed when comparing the MM patients
upon diagnosis and at D+100 ASCT were already present in
one recent QoL study from the University of Arkansas for
Medical Sciences, Little Rock, that used other indices.8
However, in Brazilian public hospitals, the economic
situation of MM patients is completely different from that of
developed countries, where all of the questionnaires were
designed. The majority of patients in this study are in
Figure 1 - A flow diagram of the study design. ASCT - autologous stem cell transplantation.
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economic class C, which means that 87.8% of the included
patients have a family budget of less than US $600/month
(i.e., economic class C, D, or E). Therefore, it is important to
apply such questionnaires in underdeveloped countries to
ensure that ASCT is a good option for their incurable
disease in this population. The QLQ-MY20 was not
validated in Portuguese (Brazilian) when the questionnaires
were applied and, therefore, was not used in our study.
Although the questionnaires are designed to be self-
completed, in this study the questionnaires were given
during interviews performed by a principal researcher. The
questionnaires were conducted in an interview because
most of the patients were considered to be functionally
illiterate and/or could not complete the forms alone. Others
could read but were unable to understand what needed to
be answered. We believe that administering the question-
naire by the same person provides more uniform results.
One criticism of this study design is that the patient groups
were not the same at the three time-points that were
investigated. This could limit the power of the observation;
however, the paired t-test results from both questionnaires
showed improvements in the patients’ QoL.
In conclusion, this study supports the use of the EORTC
QLQ-C30 as part of routine clinical care in MM patients in
developing countries. Our results also suggest that the
questionnaire for cancer patients, QLQ-C30, seems to be
more informative than the generic questionnaire, SF-36.
Table 1 - The clinical and laboratory characteristics of the 49 MM patients (upon diagnosis, post-treatment/pre-ASCT,
and D+100 ASCT). Total of 70 interviews.
Parameters Upon diagnosis
Post-treatment/
Pre-ASCT D+100 ASCT Total p-value
Sex 0.965
Female
Male
15 (21.4%)
14 (20%)
13 (18.6%)
14 (20%)
7 (10%)
7 (10%)
35 (50%)
35 (50%)
Age (years) 55.4¡13.3 53.9¡9.8 54.1¡7.8 0.856
Isotype 0.717
IgG 20 (28.6%) 21 (30%) 9 (12.9%) 50 (71.5%)
IgA 5 (7.1%) 2 (2.9%) 1 (1.4%) 8 (11.4%)
IgM 0 (0%) 1 (1.4%) 1 (1.4%) 2 (2.8%)
Light chain 3 (4.3%) 1 (1.4%) 2 (2.9%) 6 (8.6%)
Non-secretor 1 (1.4%) 2 (2.9%) 1 (1.4%) 4 (5.7%)
Stage 0.583
IA 2 (2.9%) 1 (1.4%) 0 (0%) 3 (4.3%)
IIA 1 (1.4%) 1 (1.4%) 0 (0%) 2 (2.8%)
IIIA 18 (25.7%) 19 (27.1%) 13 (18.6%) 50 (71.4%)
IIIB 8 (11.5%) 6 (8.6%) 1 (1.4%) 15 (21.5%)
ISS 0.593
1 10 (14.3%) 11 (15.7%) 5 (7.1%) 26 (37.1%)
2 9 (12.9%) 8 (11.4%) 7 (10%) 24 (34.3%)
3 10 (14.3%) 8 (11.4%) 2 (2.9%) 20 (28.6%)
ASCT - autologous stem cell transplantation.
The ages are expressed as means ¡ standard deviations.
The p-values were calculated using a chi-squared test (for the categorical variables) or ANOVA (for age).
Table 2 - Analysis of variance (ANOVA) comparing the
three groups according to the SF-36 questionnaire.
Domains
Upon
diagnosis,
Mean (¡SD)
Post-
treatment/
Pre-ASCT,
Mean (¡SD)
D+100 ASCT,
Mean (¡SD) p-value
Physical function 33 (¡33) 44 (¡27) 60 (¡25) 0.026
Role-physical 31(¡36) 47(¡28) 56 (¡29) 0.041
Bodily pain 36 (¡26) 53 (¡23) 55 (¡28) 0.025
General health 60 (¡22) 66 (¡14) 60 (¡14) 0.388
Vitality 58 (¡23) 63 (¡17) 68 (¡24) 0.364
Social function 45 (¡38) 54 (¡31) 68 (¡25) 0.094
Role-emotional 49 (¡39) 58 (¡24) 69 (¡33) 0.158
Mental health 64 (¡23) 73 (¡19) 74 (¡21) 0.194
Physical
component
33 (¡11) 37 (¡8) 40 (¡7) 0.053
Mental
component
47 (¡13) 49 (¡8) 51 (¡11) 0.362
The p-values were calculated using an ANOVA.
ASCT - autologous stem cell transplantation.
Table 3 - Analysis of variance (ANOVA) comparing the
three groups according to the QLQ-C30 questionnaire.
Scale
Upon diagnosis,
Mean (¡SD)
Post-
treatment/
Pre-ASCT,
Mean (¡SD)
D+100 ASCT,
Mean (¡SD) p-value
Global health 64 (¡24) 70 (¡22) 71 (¡16) 0.455
Functional scale
Physical 43 (¡34) 59 (¡24) 71 (¡20) 0.01
Role 39 (¡40) 72 (¡34) 83 (¡29) 0.001
Emotional 64 (¡27) 70 (¡28) 77 (¡34) 0.391
Cognitive 65 (¡30) 76 (¡23) 69 (¡24) 0.339
Social 62 (¡31) 71 (¡35) 82 (¡32) 0.186
Symptom scale
Fatigue 53 (¡31) 27(¡24) 21(¡24) 0.001
Nausea 14 (¡25) 5 (¡12) 7 (¡22) 0.289
Pain 58 (¡34) 31(¡27) 34 (¡27) 0.002
Quality of life scale
Dyspnea 15 (¡27) 5 (¡18) 7 (¡19) 0.239
Insomnia 43 (¡31) 26 (¡32) 21 (¡38) 0.061
Lack of
appetite
34 (¡47) 11(¡24) 14 (¡31) 0.046
Constipation 36 (¡43) 9 (¡20) 7(¡14) 0.002
Diarrhea 2 (¡12) 0 9 (¡20) 0.059
Financial
difficulties
53 (¡41) 30 (¡40) 31(¡38) 0.071
The p-values were calculated using an ANOVA.
QoL: Quality-of-life.
ASCT- autologous stem cell transplant.
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Additionally, the QLQ-C30 reflects the benefits of ASCT for the
QoL of MM patients from two public Brazilian institutions that
provide assistance for economically challenged patients.
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Table 4 - Post hoc tests comparing the three groups (two
by two).
POST HOC Test Group p-value
Physical function (SF-36) Upon diagnosis 0.02
D+100 ASCT {
Physical (QLQ-C30) Upon diagnosis 0.011
D+100 ASCT {
Role (QLQ-C30) Upon diagnosis 0.003
Post-treatment/Pre-ASCT {
Role (QLQ-C30) Upon diagnosis 0.001
D+100 ASCT {
Fatigue (QLQ-C30) Upon diagnosis 0.003
Post-treatment/Pre-ASCT {
Fatigue (QLQ-C30) Upon diagnosis 0.002
D+100 ASCT {
Pain (QLQ-C30) Upon diagnosis 0.003
Post-treatment/Pre-ASCT {
Pain (QLQ-C30) Upon diagnosis 0.042
D+100 ASCT {
Lack of appetite (QLQ-C30) Upon diagnosis 0.05
Post-treatment/Pre-ASCT {
Constipation (QLQ-C30) Upon diagnosis 0.005
Post-treatment/Pre-ASCT {
Constipation (QLQ-C30) Upon diagnosis 0.016
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ASCT - autologous stem cell transplantation.
{The group with the superior outcome.
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